ArticleResearch and practice in thrombosis and haemostasis2026
Induced pluripotent stem cell-derived platelets kill multidrug-resistant
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe infection caused by multidrug-resistant bacteria, such as multidrug-resistant Objectives: We aimed to verify whether iPSC-PLTs are capable of killing MRSA and further elucidate the mechanisms involved in this process. Methods: We performed Results: All 3 iPSC-PLT clones demonstrated MRSA-killing capacity. Although only minimal activation of iPSC-PLTs was observed, antiplatelet agents inhibited this killing. Notably, plasma components enhanced the bactericidal activity of iPSC-PLTs, in part via immunoglobulin G, as evidenced by inhibition with an FcγRIIA-blocking antibody. Compared with wild-type MRSA, α-toxin-deficient strains were more susceptible to iPSC-PLT-mediated killing, suggesting that α-toxin acts as a suppressor of this platelet function. Furthermore, MyD88-deficient iPSC-PLTs exhibited impaired MRSA-killing capacity, indicating the indispensable role of Toll-like receptor 2-mediated signaling in this response. Conclusion: Collectively, our findings highlight the direct antimicrobial potential of iPSC-PLTs and provide mechanistic insights, particularly into the contribution of the Toll-like receptor-MyD88 axis. This study provided a basis for applying iPSC-PLTs as a novel therapeutic modality for combating MRSA infections and a genetically modifiable platform for investigating unknown platelet function within the context of antimicrobial immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.